• Site Search
  • News
  • Product
  • Zhejiang Medical Technology Development Co., Ltd.

    2017 year
    02 day
    Boehringer-Ingelheim China and Zhejiang Medical Technology Development Co., Ltd. Established Strateg

    (November 2, 2017, Shanghai) Boehringer-Ingelheim China and Zhejiang Medical Technology Development Co., Ltd. announced that they had concluded a strategic partnership agreement. Boehringer-Ingelheim China will grant exclusive authorization for the marketing of its respiratory drug Mucosolvan® injection to Zhejiang Medical Technology  Development Co., Ltd. (hereinafter Zhejiang Medical) from January 1, 2018. Boehringer-Ingelheim is still the owner and producer of Mucosolvan® injection.

    “We are very glad to establish strategic partnership with Zhejiang Medical. The partnership not only allows Chinese patients to keep using our flagship product, Mucosolvan®injection, but also allows us to make big and sufficient resources in our abundant innovative product lines. Boehringer-Ingelheim will launch more than 10 innovative products, including the newly approved OFEV® (Nintedanib) for idiopathic Pulmonary Fibrosis (IPF), Jardiance (empagliflozin) for type-II diabetes, Twynsta® (telmisartan/amlodipine tablets) for high blood pressure and Giotrif® (afatinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC), which was launched earlier this year, in important treatment areas in short and mid-term in China. Our goal is to become a powerful competitor in the treatment areas of stroke/AF-stroke prevention, respiratory disease, cancer and diabetes and become a market leader in these areas by 2020.” Mr. Dirk Van Niekerk, General Manager of the Prescription Drug Business Department of Boehringer-Ingelheim Greater China Region, indicated.

    Mr. Wang Wei, President of Zhejiang Medical, pointed out: “Mucosolvan® injection has been used widely in clinical practice in the past 20 years and benefited countless Chinese patients. We are very honored to become a partner of Boehringer-Ingelheim China. It is our honor to provide Mucosolvan® injection, a classical and widely recognized product for respiratory disease, for Chinese patients. Over ten plus years of development, Zhejiang Medical has established a professional academic promotion system and an effective operation management system. We will make use of our network, marketing and promotion strengths around China to provide integrated service including market strategies, academic promotion, brand management, etc. for Mucosolvan® injection in order to explore higher market potential of the product and benefit more patients.”

    The conclusion of the agreement signifies that Boehringer-Ingelheim China and Zhejiang Medical have established long-term and stable strategic partnership. The two parties will keep promoting the continuous development of China’s health area with their professional influence in the industry and make contributions to China’s health undertaking.

    Boehringer-Ingelheim China and Zhejiang Medical Technology Development Co., Ltd. Established Strateg Boehringer-Ingelheim China and Zhejiang Medical Technology Development Co., Ltd. Established Strateg

    About Boehringer-Ingelheim

    In the past 130 some years, the R&D-driven pharmaceutical company Boehringer-Ingelheim has been committed to providing innovative drugs for human beings and animals. Boehringer-Ingelheim is one of the world top 20 pharmaceutical companies and has been a family business. Every day, about 50,000 employees work hard to create value through innovation in three business areas, pharmaceuticals for human use, animal health and bio-pharmaceutical contract manufacturing. In 2016, Boehringer-Ingelheim realized net sales revenue of EUR 15.9 billion. The expenditure on R&D was EUR 3 billion, equivalent to 19.6% of the net sales revenue.

    Boehringer-Ingelheim entered Chinese market in 1994 officially. At present, its total investment in China is over EUR 200 million. Boehringer-Ingelheim China is based in Shanghai and runs business nationwide. It has 3,500 employees. Boehringer-Ingelheim has developed fast in China in recent years. Three business sections, pharmaceuticals for human use, animal health and bio-pharmaceutical, develop in a balanced way to push the company to grow in a sustaining way. In Boehringer-Ingelheim China, the undertakings and care of the company to its employees, patients, business partners and the community in which it is located are seen from various aspects. It has been one of the tenets of the company to take social responsibilities since Boehringer-Ingelheim was founded. Boehringer-Ingelheim China has acquired the certification of China’s Top Employer for four years in a row from 2014 to 2017.


    About Zhejiang Medical Technology Development Co., Ltd.

    Zhejiang Medical Technology Development Co., Ltd. is a solely-owned subsidiary of HK WinHealth Pharma Group Co., Limited. It has been following the business tenet of “maintaining health and enjoying life” since it was founded. It is committed to introducing in world leading health products and medical technology into Chinese market and has established long-term partnership with a number of renowned pharmaceutical companies in respiratory, anti-infection, cardiovascular, urinary, blood and cancer areas. After years of ceaseless efforts, it has developed to a professional third-party pharmaceutical service company that can provide a complete service system from registration, import, distribution and promotion of pharmaceuticals and medical equipment. Its network has covered more than 6,000 medical institutions in over 30 provinces and cities in China. 

    3rd Floor, Winhealth Industrial Park, No. 272 Huancheng East Road, Xiacheng District, Hangzhou, Zhejiang, China
    BD@winhealth.Hk (overseas)
    0571-8718 6358    4008393773 ( Product Hotline )
    Copyright ©2019 - 2024 Zhejiang Medical Technology Development Co., Ltd.